

| All ETCTN Trials: Updated September 15, 2020 (Includes trials that are in review, approved, and active) | | | | | |
|--|---|---------------------------|---------------------------|--|---|
| CTEP Trial ID | Title | Limited/ETCTN-wide | Radiation Oncology | Disease Area(s) | ClinicalTrials.gov website (if available) |
| 9466 | Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I only) | ETCTN-wide | | Skin and other melanoma | https://clinicaltrials.gov/ct2/show/NCT01989585 |
| 9591 | A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction | ETCTN-wide | | Solid tumors (no specified mutations) | https://clinicaltrials.gov/ct2/show/NCT02070549 |
| 9673 | A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal | ETCTN-wide | | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT02314169 |
| 9676 | A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors | Limited | | Melanoma, Genitourinary, Ovarian, Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT02298959 |
| 9681 | A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors | Limited | | Genitourinary | https://clinicaltrials.gov/ct2/show/NCT02496208 |
| 9767 | An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation | ETCTN-wide | | Genitourinary | https://clinicaltrials.gov/ct2/show/NCT03108261 |

| | | | | | |
|------|---|------------|-----------|---------------------------------------|---|
| 9881 | A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors | ETCTN-wide | | Breast, Gastrointestinal, Lung | https://clinicaltrials.gov/ct2/show/NCT02498613 |
| 9892 | Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer | ETCTN-wide | Radiation | Gynecologic | https://clinicaltrials.gov/ct2/show/NCT02595879 |
| 9898 | A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor | ETCTN-wide | | Lung | https://clinicaltrials.gov/ct2/show/NCT02496663 |
| 9910 | A Phase 1 Trial of MLN0128 (TAK-228) in Combination with Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor | ETCTN-wide | | Lung | https://clinicaltrials.gov/ct2/show/NCT02503722 |
| 9914 | A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors | Limited | | Solid tumors (no specified mutations) | https://clinicaltrials.gov/ct2/show/NCT02631733 |
| 9924 | A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL) | ETCTN-wide | | Lymphoma | https://clinicaltrials.gov/ct2/show/NCT02568553 |
| 9930 | A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL) | ETCTN-wide | | Lymphoma | https://clinicaltrials.gov/ct2/show/NCT02520791 |
| 9938 | Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors | Limited | | Solid tumors (no specified mutations) | https://clinicaltrials.gov/ct2/show/NCT02595931 |

| | | | | | |
|-------|--|------------|-----------|--------------------------------------|---|
| 9948 | Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer | ETCTN-wide | | Gynecologic | https://clinicaltrials.gov/ct2/show/NCT02627443 |
| 9950 | A Phase I Study of M6620 (VX-970) in Combination with Cisplatin and XRT in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121) | ETCTN-wide | Radiation | Head and Neck/Thyroid | https://clinicaltrials.gov/ct2/show/NCT02567422 |
| 9952 | Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC) | ETCTN-wide | Radiation | Brain, Lung | https://clinicaltrials.gov/ct2/show/NCT02589522 |
| 9979 | Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUDR-Mediated Tumor Radiosensitization in Brain Metastases | ETCTN-wide | Radiation | Brain | https://clinicaltrials.gov/ct2/show/NCT02993146 |
| 10009 | A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT02936752 |
| 10014 | A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies | ETCTN-wide | | Leukemia, Lymphoma, Solid tumors (no | https://clinicaltrials.gov/ct2/show/NCT02862275 |

| | | | | specified mutations) | |
|-------|---|------------|-----------|-------------------------|---|
| 10015 | A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma | ETCTN-wide | | Sarcoma | https://clinicaltrials.gov/ct2/show/NCT03148275 |
| 10017 | A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer | ETCTN-wide | | Gynecologic | https://clinicaltrials.gov/ct2/show/NCT03206047 |
| 10020 | A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer | ETCTN-wide | | Breast | https://clinicaltrials.gov/ct2/show/NCT02849496 |
| 10026 | A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia | Limited | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT02890329 |
| 10030 | A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia | Limited | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT02879695 |
| 10056 | A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma | ETCTN-wide | Radiation | Sarcoma | https://clinicaltrials.gov/ct2/show/NCT02923778 |
| 10057 | A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + | ETCTN-wide | | Skin and other melanoma | https://clinicaltrials.gov/ct2/show/NCT02978625 |

| | | | | | |
|-------|--|------------|-----------|---------------------------------------|---|
| | Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors | | | | |
| 10058 | A Phase I Study of Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum | Limited | Radiation | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT03300544 |
| 10061 | A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors | ETCTN-wide | | Solid tumors (no specified mutations) | https://clinicaltrials.gov/ct2/show/NCT03030378 |
| 10066 | A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760) | ETCTN-wide | | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT03008278 |
| 10070 | Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors | Limited | | Lung, Solid tumors, (escalation only) | https://clinicaltrials.gov/ct2/show/NCT03366103 |
| 10075 | A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT03041688 |
| 10076 | A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma | Limited | | Myeloma | https://clinicaltrials.gov/ct2/show/NCT03031730 |
| 10089 | A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in | ETCTN-wide | | Lymphoma | https://clinicaltrials.gov/ct2/show/NCT03038672 |

| | | | | | |
|-------|---|------------|-----------|---------------|---|
| | Patients with Relapsed or Refractory Aggressive B-cell Lymphomas | | | | |
| 10096 | A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE) | ETCTN-wide | Radiation | Genitourinary | https://clinicaltrials.gov/ct2/show/NCT03317392 |
| 10100 | A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option | ETCTN-wide | | Genitourinary | https://clinicaltrials.gov/ct2/show/NCT03237780 |
| 10104 | A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer | ETCTN-wide | | Gynecologic | https://clinicaltrials.gov/ct2/show/NCT03367741 |
| 10106 | A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large B- Cell Lymphoma | ETCTN-wide | | Lymphoma | https://clinicaltrials.gov/ct2/show/NCT03309878 |
| 10107 | Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma | ETCTN-wide | | Lung | https://clinicaltrials.gov/ct2/show/NCT03126630 |
| 10126 | A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for | ETCTN-wide | | Lymphoma | https://clinicaltrials.gov/ct2/show/NCT03321643 |

| | | | | | |
|-------|---|------------|--|--|---|
| | Transformed Diffuse Large B-Cell Lymphoma | | | | |
| 10129 | A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors | ETCTN-wide | | Brain, Gastrointestinal, Solid tumors (mutations) | https://clinicaltrials.gov/ct2/show/NCT03212274 |
| 10131 | Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel | Limited | | Breast, Genitourinary, Solid tumors (mutations; escalation only) | https://clinicaltrials.gov/ct2/show/NCT03218826 |
| 10136 | A Phase 2 Trial of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification | ETCTN-wide | | Solid tumors (mutations) | https://clinicaltrials.gov/ct2/show/NCT03253679 |
| 10144 | A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects | ETCTN-wide | | Genitourinary | https://clinicaltrials.gov/ct2/show/NCT03375307 |
| 10145 | Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas | Limited | | Lymphoma, Solid tumors (no specified mutations) | https://clinicaltrials.gov/ct2/show/NCT03502733 |
| 10146 | Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer | ETCTN-wide | | Breast | https://clinicaltrials.gov/ct2/show/NCT03606967 |
| 10147 | A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML) | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT03289910 |

| | | | | | |
|-------|--|------------|-----------|--------------------------|---|
| 10150 | A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer | ETCTN-wide | | Gynecologic | https://clinicaltrials.gov/ct2/show/NCT03587311 |
| 10166 | A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer | ETCTN-wide | | Lung | https://clinicaltrials.gov/ct2/show/NCT03600701 |
| 10170 | A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies | ETCTN-wide | | Solid tumors (mutations) | https://clinicaltrials.gov/ct2/show/NCT03284385 |
| 10181 | A Phase II Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer | ETCTN-wide | | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT03592641 |
| 10183 | A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma | ETCTN-wide | | Genitourinary | https://clinicaltrials.gov/ct2/show/NCT03854474 |
| 10184 | Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | ETCTN-wide | Radiation | Head and Neck/Thyroid | https://clinicaltrials.gov/ct2/show/NCT03803774 |
| 10186 | A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma | ETCTN-wide | Radiation | Brain | https://clinicaltrials.gov/ct2/show/NCT03604978 |
| 10191 | Phase 2 Study of M6620 in Combination with Carboplatin Compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer | ETCTN-wide | | Genitourinary | https://clinicaltrials.gov/ct2/show/NCT03517969 |
| 10193 | Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory | ETCTN-wide | | Lymphoma | https://clinicaltrials.gov/ct2/show/NCT03484819 |

| | | | | | |
|-------|---|------------|--|---|---|
| | Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma | | | | |
| 10195 | A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor | ETCTN-wide | | Breast | https://clinicaltrials.gov/ct2/show/NCT03803761 |
| 10200 | A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia | Limited | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT03701295 |
| 10204 | Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) | ETCTN-wide | | Solid tumors (no specified mutations), Lymphoma | https://clinicaltrials.gov/ct2/show/NCT03816345 |
| 10208 | A Phase I/II study of Anetumab Ravnansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma | ETCTN-wide | | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT03816358 |
| 10211 | A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer | ETCTN-wide | | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT03641313 |
| 10212 | A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT03724084 |
| 10214 | Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers | ETCTN-wide | | Skin and other melanoma | https://clinicaltrials.gov/ct2/show/NCT03816332 |

| | | | | | |
|-------|--|------------------------|-----------|--|---|
| 10216 | A Phase Ib/II Study of Osimertinib and CB-839 in Patients with EGFR Mutant Non-Small Cell Lung Cancer | ETCTN-wide | | Lung | https://clinicaltrials.gov/ct2/show/NCT03831932 |
| 10217 | A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors | Limited | | Solid tumors (mutations) | https://clinicaltrials.gov/ct2/show/NCT03842228 |
| 10218 | A Phase Ib Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma | ETCTN-wide | Radiation | Brain | https://clinicaltrials.gov/ct2/show/NCT03528642 |
| 10219 | Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | ETCTN-wide | | Myeloma | https://clinicaltrials.gov/ct2/show/NCT03798678 |
| 10220 | A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors | ETCTN-wide | | Solid tumors (mutations), Brain | https://clinicaltrials.gov/ct2/show/NCT03872427 |
| 10221 | Phase I/II Biomarker-Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors | Limited (Phase 1 only) | | Solid tumors (mutations) | https://clinicaltrials.gov/ct2/show/NCT04317105 |
| 10222 | A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors | ETCTN-wide | | Gastrointestinal, Solid tumors (mutations) | https://clinicaltrials.gov/ct2/show/NCT03878095 |
| 10237 | A Phase 1 Study of TAK-243 for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT03816319 |

| | | | | | |
|-------|--|------------|--|--|---|
| | Myelomonocytic Leukemia Refractory to Hypomethylating Agents | | | | |
| 10240 | Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy | ETCTN-wide | | Head and Neck/Thyroid | https://clinicaltrials.gov/ct2/show/NCT03914300 |
| 10244 | Phase I Study of GSK525762 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas | ETCTN-wide | | Lymphoma, Solid tumors (dose escalation) | https://clinicaltrials.gov/ct2/show/NCT03925428 |
| 10246 | A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Limited | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT03772925 |
| 10247 | A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT03745352 |
| 10249 | MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial | ETCTN-wide | | Myeloma | https://clinicaltrials.gov/ct2/show/NCT03770260 |
| 10264 | The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT03953898 |
| 10266 | A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with | ETCTN-wide | | Lung | https://clinicaltrials.gov/ct2/show/NCT03965689 |

| | | | | | |
|-------|--|-------------------|-----------|--|---|
| | Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy | | | | |
| 10268 | Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer | ETCTN-wide | | Lung | https://clinicaltrials.gov/ct2/show/NCT03896503 |
| 10273 | A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT03983824 |
| 10276 | A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | Limited (Phase 1) | Radiation | Gastrointestinal, Solid tumors (dose escalation) | https://clinicaltrials.gov/ct2/show/NCT04068194 |
| 10285 | Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma who Progressed on Prior BRAF/MEK Inhibitor Therapy | ETCTN-wide | | Skin and other melanoma | Not available at this time. |
| 10286 | Phase II Pilot Evaluation of Tazemetostat in Combination with Cisplatin/Pemetrexed as First-Line Therapy for Pleural Mesothelioma | ETCTN-wide | | Lung | Not available at this time. |
| 10287 | A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA) | ETCTN-wide | | Breast | https://clinicaltrials.gov/ct2/show/NCT03939897 |
| 10291 | A Phase 1b Study of M6620 in Combination with Radiation Therapy | ETCTN-wide | Radiation | Breast | https://clinicaltrials.gov/ct2/show/NCT04052555 |

| | | | | | |
|-------|--|-------------------|-----------|---|---|
| | to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | | | | |
| 10292 | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors | ETCTN-wide | | Solid tumors (no specified mutations) | https://clinicaltrials.gov/ct2/show/NCT03907475 |
| 10295 | A Phase 1/2 Study of the Bromodomain Inhibitor Molibresib in Combination with Etoposide/Platinum in Patients with NUT Carcinoma | ETCTN-wide | | Solid tumors (mutations) | https://clinicaltrials.gov/ct2/show/NCT04116359 |
| 10296 | Phase Ib/II Trial of Copanlisib in Combination with Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) with PIK3CA Mutation or PTEN Mutation | Limited (Phase 1) | | Breast | https://clinicaltrials.gov/ct2/show/NCT04108858 |
| 10299 | A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients | ETCTN-wide | | Lymphoma, Solid tumors (no specified mutations) | Not available at this time. |
| 10300 | BLAST MRD AML-1: A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT04214249 |
| 10301 | A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | ETCTN-wide | Radiation | Genitourinary | https://clinicaltrials.gov/ct2/show/NCT04071236 |

| | | | | | |
|-------|---|------------------------|-----------|---------------------------------------|---|
| 10302 | Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer | ETCTN-wide | Radiation | Breast | https://clinicaltrials.gov/ct2/show/NCT04090398 |
| 10313 | A Phase IB and Randomized Open-Label Phase II Study of M6620 in Combination with Carboplatin/Gemcitabine/Avelumab in Patients with Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology | ETCTN-wide | | Lung | https://clinicaltrials.gov/ct2/show/NCT04216316 |
| 10315 | A Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas | ETCTN-wide | | Solid tumors (no specified mutations) | https://clinicaltrials.gov/ct2/show/NCT04079712 |
| 10317 | A Pilot Study of Nivolumab in Combination with Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia | Limited | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT04277442 |
| 10324 | A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) | Limited | | Gynecologic | https://clinicaltrials.gov/ct2/show/NCT04092270 |
| 10327 | A Phase I Trial of MLN0128(TAK-228) and CB-839 HCL (telaglenastat) in Advanced NSCLC Patients | Limited | | Lung | https://clinicaltrials.gov/ct2/show/NCT04250545 |
| 10329 | Phase I Sequential Trial of Agents Against DNA Repair (STAR) | Limited (Phase 1 only) | | Solid tumors (mutations) | https://clinicaltrials.gov/ct2/show/NCT04197713 |
| 10330 | A Phase II Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and | ETCTN-wide | | Sarcoma | https://clinicaltrials.gov/ct2/show/NCT04340843 |

| | | | | | |
|-------|---|------------|--|--|---|
| | Metastatic Conventional Chondrosarcoma | | | | |
| 10334 | BLAST MRD AML-2: A Randomized Phase 2 Study of Venetoclax, Azacitadine, and Pembrolizumab Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia Who Are Ineligible or Who Refuse Intensive Chemotherapy | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT04284787 |
| 10335 | A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) | ETCTN-wide | | Leukemia, Lymphoma | https://clinicaltrials.gov/ct2/show/NCT04301076 |
| 10346 | Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-Expressing Advanced Solid Tumors | Limited | | Solid tumors (mutations) | https://clinicaltrials.gov/ct2/show/NCT04294628 |
| 10347 | A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS) | ETCTN-wide | | Lymphoma | Not available at this time. |
| 10349 | A Phase I Trial of the P97 Inhibitor CB-5339 in Patients with Advanced Solid Tumors and Lymphomas | Limited | | Lymphoma, Solid tumors (no specified mutations) | https://clinicaltrials.gov/ct2/show/NCT04372641 |
| 10355 | A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies | ETCTN-wide | | Solid tumors (mutations), solid tumor dose escalation, gynecologic | Not available at this time. |
| 10358 | Phase 1/1B study of DS8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial) | ETCTN-wide | | Gastrointestinal, Solid tumors (dose escalation) | Not available at this time. |
| 10363 | A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus- | Limited | | Lymphoma, Solid tumors (no | Not available at this time. |

| | Associated Malignancies in Patients with or Without HIV | | | specified mutations) | |
|-------|--|-------------------|-----------|---|---|
| 10366 | A Phase 1/2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma | ETCTN-wide | Radiation | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT04172532 |
| 10367 | A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML) | ETCTN-wide | | Leukemia | https://clinicaltrials.gov/ct2/show/NCT04190550 |
| 10371 | A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response | Limited | | Solid tumors (mutations) | Not available at this time. |
| 10382 | A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer | Limited (Phase 1) | | Breast | https://clinicaltrials.gov/ct2/show/NCT04345913 |
| 10384 | A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma | ETCTN-wide | | Lymphoma | https://clinicaltrials.gov/ct2/show/NCT04541017 |
| 10387 | Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection | Limited | | Sarcoma, Solid tumors (dose escalation) | https://clinicaltrials.gov/ct2/show/NCT04514484 |
| 10388 | A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive | ETCTN-wide | Radiation | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT04234568 |

| | | | | | |
|-------|---|------------|-----------|---|---|
| | Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | | | | |
| 10389 | A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) with Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer | ETCTN-wide | Radiation | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT04460937 |
| 10398 | A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma | ETCTN-wide | | Sarcoma | https://clinicaltrials.gov/ct2/show/NCT04458922 |
| 10399 | A Phase 1 Study of Entinostat in Combination with Atezolizumab / Carboplatin / Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer | ETCTN-wide | | Lung | Not available at this time. |
| 10401 | A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma | ETCTN-wide | | Gynecologic | https://clinicaltrials.gov/ct2/show/NCT04494113 |
| 10402 | BAY1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA) | ETCTN-wide | | Gastrointestinal, Lung, Solid tumors (dose escalation) | https://clinicaltrials.gov/ct2/show/NCT04514497 |
| 10403 | Phase 1 Trial of Gemcitabine Combined with the BAY1895344 ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer | ETCTN-wide | | Gastrointestinal, Gynecologic, Solid Tumors (dose escalation) | Not available at this time. |

| | | | | | |
|-------|--|------------|-----------|---|---|
| 10404 | A Phase I Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma | ETCTN-wide | | Genitourinary, Solid tumors (dose escalation) | https://clinicaltrials.gov/ct2/show/NCT04491942 |
| 10405 | Phase 1 Trial of BAY1895344 ATR Inhibitor Combined with Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma | ETCTN-wide | | Head and Neck Cancer, Radiation | Not available at this time. |
| 10406 | Phase 1/1b Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers | ETCTN-wide | | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT04535401 |
| 10410 | A Phase 1 Study of IPdR in Combination with Capecitabine and Radiotherapy in Rectal Cancer | ETCTN-wide | Radiation | Gastrointestinal | https://clinicaltrials.gov/ct2/show/NCT04406857 |
| 10411 | Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST) | Limited | | Sarcoma | Not available at this time. |
| 10422 | Abemaciclib and Olaparib for Recurrent Ovarian Cancer | ETCTN-wide | | Gynecologic | Not available at this time. |
| 10437 | A Single Arm Phase II Study of Bone-Targeted Sn-117m-DTPA in Symptomatic Castration Resistant Prostate Cancer with Skeletal Metastases | ETCTN-wide | Radiation | Genitourinary | Not available at this time. |